307 related articles for article (PubMed ID: 31359863)
1. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
2. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
Limmroth V; Bayer-Gersmann K; Mueller C; Schürks M
JMIR Form Res; 2022 Mar; 6(3):e31972. PubMed ID: 35285806
[TBL] [Abstract][Full Text] [Related]
3. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT
Köhler W; Bayer-Gersmann K; Neußer T; Schürks M; Ziemssen T
Front Neurol; 2021; 12():643126. PubMed ID: 33716945
[No Abstract] [Full Text] [Related]
5. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
[TBL] [Abstract][Full Text] [Related]
6. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
7. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
Patti F; Penaherrera JN; Zieger L; Wicklein EM
BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
11. Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT
Butler O; Heeg S; Holl K; Frenz AK; Wicklein EM; Rametta M; Yeo S
Drugs Real World Outcomes; 2021 Sep; 8(3):359-367. PubMed ID: 33928518
[TBL] [Abstract][Full Text] [Related]
12. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
13. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector.
Farej R; Rametta M; La Rose A; Quillen A; McLeod K
Neurol Ther; 2022 Mar; 11(1):373-384. PubMed ID: 35064907
[TBL] [Abstract][Full Text] [Related]
15. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
Zecca C; Disanto G; Mühl S; Gobbi C
BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
[TBL] [Abstract][Full Text] [Related]
16. Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
Zettl UK; Schreiber H; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Hecker M;
Acta Neurol Scand; 2017 Aug; 136(2):116-121. PubMed ID: 27796033
[TBL] [Abstract][Full Text] [Related]
17. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study.
Kotterba S; Neusser T; Norenberg C; Bussfeld P; Glaser T; Dörner M; Schürks M
BMC Neurol; 2018 Aug; 18(1):123. PubMed ID: 30143019
[TBL] [Abstract][Full Text] [Related]
18. BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT
Patti F; Martínez Ginés ML; Norenberg C; Duarte Caron F
Patient Prefer Adherence; 2020; 14():771-779. PubMed ID: 32425509
[TBL] [Abstract][Full Text] [Related]
19. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
[TBL] [Abstract][Full Text] [Related]
20. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.
Pozzilli C; Schweikert B; Ecari U; Oentrich W;
J Neurol Sci; 2011 Aug; 307(1-2):120-6. PubMed ID: 21636099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
